Floatz logo

Ex Vivo-Expanded Her2-Specific T Cells

Recurrent Breast Cancer

University of WashingtonCell therapyPhase 1/2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

891 Active assets in the Recurrent Breast Cancer cohort.

Asset / SponsorPhaseRating
Lapatinib
University of New Mexico
Phase 3BBB
Darolutamide
Vandana Abramson
Phase 2BBB
Trastuzumab Duocarmazine
Byondis B.V.
Phase 3BB
ERIBULIN MONOMETHANESULFONATE
Henan Cancer Hospital
Phase 4BB
Palbociclib
Hoffmann-La Roche
Phase 4BB

View all 50 →

Same molecule, other indications

Ex Vivo-Expanded Her2-Specific T Cells is also rated in:

breast carcinomaDormant
B
Indicative ·
57 / 100
View asset →
male breast carcinomaDormant
CCC
Indicative ·
55 / 100
View asset →
HER2 positive breast carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →